Related Experiment Video

Updated: Jul 11, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy

F Guarracino1, C Cariello, A Danella

  • 1Cardiothoracic Anaesthesia and Intensive Care Unit, Cardiothoracic Department, University Hospital of Pisa, Italy. fabiodoc64@hotmail.com

Acta Anaesthesiologica Scandinavica
|September 14, 2007
PubMed

Insights

Levosimendan improves ventriculo-arterial coupling in patients with left ventricular dysfunction. This drug enhances myocardial contractility and reduces arterial elastance, boosting cardiovascular performance.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Levosimendan is a calcium sensitizer that enhances myocardial contractility and dilates peripheral arteries.
  • Ventriculo-arterial coupling (Ea/Ees) assesses cardiovascular efficiency by relating ventricular and arterial elastance.
  • Ischemic cardiomyopathy presents challenges in maintaining adequate cardiac output.

Purpose of the Study:

  • To evaluate the effects of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy.
  • To assess changes in myocardial contractility and arterial system interaction.
  • To determine the drug's impact on overall cardiovascular performance.

Main Methods:

  • Prospective clinical investigation involving 15 patients with stable angina and left ventricular dysfunction.
  • Invasive monitoring and transesophageal echocardiography were used to assess cardiovascular variables.
  • Levosimendan was administered as a 12 mug/kg bolus before coronary surgery.

Main Results:

  • Levosimendan significantly increased cardiac index and ejection fraction.
  • Mean arterial pressure and systemic vascular resistances were significantly decreased.
  • Arterial elastance (Ea) decreased, while ventricular elastance (Ees) increased, significantly improving the Ea/Ees ratio.

Conclusions:

  • Levosimendan effectively improves ventriculo-arterial coupling in coronary patients with left ventricular dysfunction.
  • The drug enhances myocardial contractility and reduces arterial elastance, leading to better cardiovascular performance.
  • Levosimendan represents a potential therapeutic option for managing cardiac dysfunction in this patient population.
Abstract

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...